文献速递肝病

原发性硬化性胆管炎的药物治疗:我们学到了什么,又将走向何方?

Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
PubMed 文献 · Hepatology · 2024-11-22

本文综述原发性硬化性胆管炎(PSC)药物治疗的循证困境。对熊去氧胆酸,临床实践指南仅给出模糊推荐,导致处方率因地方报销政策和医生偏好而异。药物研发困难部分源于对关键疾病过程认识不足、未能识别候选药物的相关作用机制,以及疾病病程个体内和个体间变异大、缺乏稳健的临床试验成功定义。尽管缺乏理想II期和III期研究设计的共识,多种化合物的多项试验正在进行,显示从治疗虚无主义转向希望。在等待当前测试药物的稳健疗效数据期间,当前缺乏有效干预不应促使基于低质量证据为PSC患者处方化合物。

要点

  • 对PSC药物治疗的显著临床获益难以建立稳健证据。
  • 熊去氧胆酸的指南推荐模糊,处方率因地方报销政策和医生偏好而异。
  • 多种化合物的多项试验正在进行,显示从治疗虚无主义转向希望。

核心结论

  • 尽管缺乏理想II期和III期研究设计的共识,多种化合物的多项试验正在进行,显示从治疗虚无主义转向希望。
  • 在等待当前测试药物的稳健疗效数据期间,当前缺乏有效干预不应促使基于低质量证据为PSC患者处方化合物。

研究设计与样本

  • 本文为综述文章,基于既往和正在进行的关键临床试验讨论PSC药物治疗的不确定性与挑战。

主要发现

  • 对PSC药物治疗的显著临床获益难以建立稳健证据。
  • 对熊去氧胆酸,临床实践指南仅给出模糊推荐,导致处方率因地方报销政策和医生偏好而异。
  • 药物研发困难部分与对关键疾病过程认识不足及未能识别候选药物的相关作用机制有关。
  • 疾病病程个体内和个体间变异大,且缺乏PSC临床试验成功的稳健定义,也导致试验阴性结果。

临床怎么用

  • 当前缺乏有效干预不应促使基于低质量证据为PSC患者处方化合物。

局限性

  • 对PSC药物治疗的显著临床获益难以建立稳健证据。
  • 对熊去氧胆酸,临床实践指南仅给出模糊推荐。
  • 药物研发困难部分与对关键疾病过程认识不足及未能识别候选药物的相关作用机制有关。
  • 疾病病程个体内和个体间变异大,且缺乏PSC临床试验成功的稳健定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It has proven difficult to establish robust evidence for significant clinical benefits of medical treatment in primary sclerosing cholangitis (PSC). For ursodeoxycholic acid, clinical practice guidelines only offer vague recommendations, leading to a situation of variable prescription rates depending on local reimbursement policies and physician preference. The difficulty in drug development in PSC is partly related to a poor understanding of critical disease processes with failure to identify relevant mechanisms of action of putative drugs. The variable disease course, both intra-individually and between individuals, and the lack of robust definitions of what success looks like for clinical trials in PSC have also contributed to the negative outcomes of trials performed. In this review article, we will discuss these uncertainties and challenges, building on key previous and ongoing clinical trials. Despite the lack of consensus for ideal phase II and phase III study designs, several trials for diverse compounds are currently ongoing, indicating a shift from therapeutic nihilism toward hope for people with PSC. While waiting for robust efficacy data for drugs currently being tested, the current lack of effective interventions should not motivate the prescription of compounds to people with PSC based on low-quality evidence.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Karlsen TH, Kaasen Jørgensen K, Bergquist A, et al. Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going? Hepatology. 2024. PMID: 39585345. doi:10.1097/HEP.0000000000001172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。